-
Mashup Score: 26
The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada. While localized prostate cancer has a five-year survival rate of more than 90%, survival decreases to 31% in the advanced or metastatic stage. 1 Current standard of care for patients with mCRPC includes treatment with androgen receptor pathway inhibitors followed by taxane-based chemotherapy. 2-5 However, due to poor prognosis associated with previously treated
Source: www.merck.comCategories: General Medicine NewsTweet
-
Mashup Score: 6Institute for Prostate Cancer Research - 18 day(s) ago
The institute is a collaborative effort of Fred Hutch Cancer Center and UW Medicine. A natural outgrowth of established research and clinical collaborations, the IPCR brings together a world-renowned team whose mission is to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics and improve survival and quality of life.
Source: www.fredhutch.orgCategories: General Medicine NewsTweet-
Together, we raised more than $4 million to accelerate breakthroughs and redefine what’s possible for #prostatecancer patients! Learn more about the Institute for Prostate Cancer Research 👉 https://t.co/LbvL8NBn0O and the Campaign for Fred Hutch 👉 https://t.co/II6koWRnk3 https://t.co/NoBO6vcz0c
-
-
Mashup Score: 0Recovery of Erectile Function in Men Undergoing Prostatectomy Tied With Surgeon Performance - 18 day(s) ago
Investigators assessed which aspects of surgical performance during radical prostatectomy improve the chances of good functional outcomes.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
Recovery of erectile function after radical prostatectomy is associated with higher surgeon skill. https://t.co/25MVqIN9jv #prostatecancer
-
-
Mashup Score: 27Real-World Evidence Informs Clinical Decision-Making in Metastatic Castration-Resistant Prostate Cancer - Alan Bryce - 18 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alan Bryce, MD, Chief Clinical Officer, City of Hope Cancer Center Pheonix, Phoenix, Arizona Elena Castro, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain Related Content: An Overview in…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Real-world evidence informs clinical decision-making in metastatic castration-resistant #ProstateCancer. @AlanBryce9 @cityofhope joins @Ecastromarcos in this discussion as part of an Independent Medical Education Initiative supported by @BayerPharma > https://t.co/W3eCflNlhO https://t.co/wivvWqyWuf
-
-
Mashup Score: 10Mary-Claire King - 20 day(s) ago
Mary-Claire King 2025 Technical and Scientific Research
Source: www.fpa.esCategories: General Medicine NewsTweet-
Prof. Mary-Claire King has been named the 2025 Princess of Asturias Award laureate for science — amazing recognition. Her work on the BRCA1/2 genes led to transforming cancer care, including for men with #ProstateCancer https://t.co/x51NAhf9qw @PCF_Science @criscancer
-
-
Mashup Score: 8
Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and
Source: www.thelancet.comCategories: General Medicine NewsTweet-
📢 For this month's podcast, we talk to Richard Bryant on transperineal vs transrectal biopsy for #prostatecancer (TRANSLATE) https://t.co/zwluRcwMPD https://t.co/CwVLWJrSX4
-
-
Mashup Score: 6Institute for Prostate Cancer Research - 20 day(s) ago
The institute is a collaborative effort of Fred Hutch Cancer Center and UW Medicine. A natural outgrowth of established research and clinical collaborations, the IPCR brings together a world-renowned team whose mission is to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics and improve survival and quality of life.
Source: www.fredhutch.orgCategories: General Medicine NewsTweet-
Together, we raised more than $4 million to accelerate breakthroughs and redefine what’s possible for #prostatecancer patients! Learn more about the Institute for Prostate Cancer Research 👉 https://t.co/LbvL8NBn0O and the Campaign for Fred Hutch 👉 https://t.co/II6koWRnk3 https://t.co/NoBO6vcz0c
-
-
Mashup Score: 1BULLSEYE: Lu-PSMA in Oligometastatic HSPC | GU Oncology Now - 20 day(s) ago
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Source: www.guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🎯 @DrScottTagawa chats with Dr. Bastiaan Privé of @radboudumc on the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic hormone sensitive #prostatecancer: https://t.co/zAsE0J5gK1 ❗️ Following surgery and external beam radiotherapy, this option has the https://t.co/kvBcPexgid
-
-
Mashup Score: 1Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor - 20 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A. Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Rana McKay, MD , Medical Oncologist, Associate Professor of…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Case-based discussion on navigating the evolving landscape of castrate-resistant #ProstateCancer management. Oliver Sartor, MD @MayoClinic joins @DrRanaMcKay @UCSanDiego as part of an independent medical education initiative on UroToday > https://t.co/ygi8XDjAQC @BayerPharma https://t.co/OZG83QZgbB
-
-
Mashup Score: 2An Overview of Strategies and Therapeutic Advances in Metastatic Prostate Cancer - Rana McKay - 22 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Rana McKay, MD, Medical Oncologist, Associate Professor of Medicine, UC San Diego School of Medicine, San Diego, CA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
An overview of strategies and therapeutic advances in metastatic #ProstateCancer. @DrRanaMcKay @UCSanDiego joins Neal Shore, MD, FACS @CURCMB in this exciting discussion as part of an Independent Medical Education Initiative on UroToday > https://t.co/8zW3edi1KO @BayerPharma https://t.co/ZN8H9dqHe8
-
Today, we announced the initiation of a Phase 3 trial in metastatic castration-resistant #prostatecancer, in collaboration with @DaiichiSankyoUS. Learn more: https://t.co/MuajcLDOza https://t.co/DrlP4wJ2rA